Laboratoires Majorelle’s history began in 2012, a year marked by the contraceptive pill crisis in France.
The 3rd generation contraceptive pill was the focus of a great deal of media attention related to the risk of venous thrombosis, which was becoming a true public health problem.
With its expertise and an approach based on the experiences of patients and the assistance provided to them, Laboratoires Majorelle developed a new range of contraceptive pills that were unlike any others on the market. Majorelle contraceptive pills are taken continuously over a 28-day cycle to make it easier for women to adhere to the regimen without fail. Optilova1,2 and Optidril1,2 are the next generation of contraceptive pills reimbursed by social security.
1 Avis de la Commission de la Transparence Optilova – Optidril
2 Document d’aide à la prescription